

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (original) An antibody or antibody derivative against factor IX/factor IXa which increases the procoagulant activity of FIXa.

2. (original) An antibody or antibody derivative according to claim 1, wherein said antibody or antibody derivative increases the procoagulant activity of FIXa in the presence of FVIII inhibitors.

3. (currently amended) An antibody or antibody derivative according to any one of claim 1 wherein said antibody is selected from the group consisting of IgG, IgM, IgA and IgE antibodies.

4. (original) An antibody or antibody derivative according to claim 1, wherein said antibody or antibody derivative is selected from the group consisting of monoclonal antibodies, antibody fragments, chimeric antibodies, humanized antibodies, single chain antibodies, bispecific antibodies, diabodies, and di-, oligo- or multimers thereof.

5-6. (cancelled)

7. (currently amended) An antibody or antibody derivative according to claim 6 claim 1, wherein said a CDR3 peptide of the antibody or antibody derivative comprises an amino acid sequence selected from the group consisting of:

~~Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr;~~

Cys-X-X-Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr-X-X-Cys, (SEQ ID NO:105) wherein X may be any desired amino acid;

Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr (SEQ ID NO:5); and

Asp-Gly-Gly-His-Gly-Tyr-Gly-Ser-Ser-Phe-Asp-Tyr (SEQ ID NO:6); and  
~~Phe Arg Asn Arg Gly Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp.~~

8. (previously presented) An antibody or antibody derivative according to claim 1, wherein the variable region of said antibody or antibody derivative comprises amino acids 1-119 and/or amino acids 135-242 as listed in SEQ ID NO:82.

9. (original) An antibody or antibody derivative according to claim 8, wherein said antibody or antibody derivative additionally comprises an artificial linker sequence.

10. (previously presented) An antibody or antibody derivative according to claim 1, wherein the variable region of said antibody or antibody derivative comprises amino acids 1-121 and/or amino acids 137-249 as listed in SEQ ID NO:84.

11. (previously presented) An antibody or antibody derivative according to claim 10, wherein said antibody or antibody derivative additionally comprises an artificial linker sequence.

12. (previously presented) An antibody or antibody derivative according to claim 1, wherein the variable region of said antibody or antibody derivative comprises amino acids 1-122 and/or amino acids 138-249 as listed in SEQ ID NO:86.

13. (original) An antibody or antibody derivative according to claim 12, wherein said antibody or antibody derivative additionally comprises an artificial linker sequence.

14. (currently amended) A hybridoma cell line expressing secreting an antibody or antibody derivative against factor IX/factor IXa according to claim 1.

15. (previously presented) A hybridoma cell line according to claim 14, wherein said cell line is selected from the group consisting of cell lines having ECACC deposit numbers 99090924, 99090925, 99090926, 99121614, 99121615, 99121616, 99121617, 99121618, 99121619 and 99121620.

16. (currently amended) An antibody or antibody derivative ~~according to claim 1~~, which is expressed secreted by a hybridoma cell line according to claim 14.

17. (cancelled)

18. (original) A pharmaceutical preparation comprising an antibody or antibody derivative according to claim 1 and a pharmaceutically acceptable carrier.

19. (original) A preparation according to claim 18, additionally comprising factor IX $\alpha$  and/or factor IX $\beta$ .

20-22. (cancelled)

23. (currently amended) A method of obtaining an antibody or antibody derivative which interacts with factor IX/factor IXa and increases the procoagulant activity of Factor IXa, comprising the steps of:

immunizing an immunocompetent mouse with an antigen selected from the group consisting of FIX, FIX $\alpha$ , FIX $\beta$  or fragments thereof,

isolating spleen cells of the immunized mouse,

producing hybridoma ~~clones~~ cells,

screening the hybridoma cell supernatants for an increase in the procoagulant activity of Factor IXa, isolating and purifying the antibodies or antibody derivatives from hybridoma cell supernatants which exhibit an increase in the procoagulant activity of factor IXa.

24. (cancelled)

25. (currently amended) An antibody or antibody derivative according to claim 4, which is an antibody fragment.

26. (currently amended) An antibody or antibody derivative according to claim 4, which is a single chain antibody.

27. (currently amended) An antibody or antibody derivative according to claim 4, which is a humanized antibody.

28. (new) An antibody or antibody derivative against factor IX/IXa having FVIII-cofactor-like activity which exhibits in a FVIII assay after two hours of incubation a ratio of background to measured value of at least 3.

29. (new) An antibody or antibody derivative according to claim 2 wherein said antibody is selected from the group consisting of IgG, IgM, IgA and IgE antibodies.